Australian sepsis study to power new antibiotic discoveries

Petri dish used for bacterial research

University of Queensland (UQ) researchers have led a national study on the four main bacteria that cause sepsis, providing new targets for developing antibiotics.

Professor Mark Walker and Professor Mark Schembri from UQ’s Institute for Molecular Bioscience, along with Dr Andre Mu from the University of Melbourne and teams from 23 research organisations around Australia, set up experiments to mimic what happens to bacteria when they enter the bloodstream during infection.

Sepsis causes 20% of deaths worldwide, killing more people than heart attacks, stroke, or cancers of the prostate, breast or colon. It is characterised by infection-associated organ failure, leaving survivors with physical, cognitive and psychological side effects that can persist for the rest of their lives.

The research team set out to find responses common to all four types of bacteria that cause sepsis and discover more about how bacteria survive in the body.

“Currently when someone goes to hospital with sepsis they are immediately treated with antibiotics, which may have to be adjusted once the type of bacteria has been identified,” Professor Walker said. “This study allowed us to identify potential new targets for antibiotics that target all sepsis-causing bacteria.”

He added: “We have been able to characterise bacterial genes, RNA, proteins and metabolites from E. coli, Group A Streptococcus, Klebsiella pneumoniae and Staphylococcus aureus and integrated the data to get a complete picture of how different species respond when grown in human blood serum.”

The data is now publicly available to researchers around the world to support antibiotic discovery and development.

The Antibiotic Resistant Sepsis Pathogens Framework Initiative consortium is supported by funding from Bioplatforms Australia, enabled by the Australian Government National Collaborative research infrastructure Strategy (NCRIS).

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free